LR-90

• Description :

  LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes[1]. LR-90 is also used in the research of diabetic animal model[2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  COX

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/LR-90.html

• Purity :

  99.24

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(NC1=CC=C(C=C1)OC(C)(C)C(O)=O)NC(C(Cl)=C2)=CC=C2CC3=CC=C(C(Cl)=C3)NC(NC4=CC=C(C=C4)OC(C)(C)C(O)=O)=O

• Molecular Formula :

  C35H34Cl2N4O8

• Molecular Weight :

  709.57

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56 (3) :647-55.|[2]Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51 (5) :882-91.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [245075-84-7]